DJIA 17,827.75 0.00 0.00%
NASDAQ 4,787.32 0.00 0.00%
S&P 500 2,072.83 0.00 0.00%
market minute promo

Exelixis (NASDAQ: EXEL)

1.76 0.00 (0.00%)

REAL-TIME: Last trade at

Extended Hours: $1.76 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

EXEL $1.76 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.72
Previous Close $1.76
Daily Range $1.68 - $1.76
52-Week Range $1.35 - $8.41
Market Cap $343.6M
P/E Ratio -1.17
Dividend (Yield) $0.00 (0.0%)
Volume 1,090,735
Average Daily Volume 1,908,265
Current FY EPS -$1.41

Sector

Healthcare

Industry

Drugs

Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website: http://www.exelixis.com/

News & Commentary

Exelixis' Cometriq Makes a Comeback

Exelixis reports third quarter earnings, but it's the data testing Cometriq in lung cancer that's caused the stock pop.

Exelixis: Why This Company Could Become The Next Dendreon

Update: Exelixis Announces Very Positive Phase 1 Trial Data

Biotech Weekly: Here Come The Institutional Holdings Updates

Update: Exelixis Reports Q3 Earnings - Impact To My Thesis

Exelixis' (EXEL) CEO Mike Morrissey on Q3 2014 Results - Earnings Call Transcript

Exelixis (EXEL) Q3 2014 Results - Earnings Call Webcast

Why Exelixis, Inc. Stock Pushed 11% Higher in October

Exelixis was one of the best biotech stocks in October. Find out what sent its shares higher by 11% and whether or not the good times will keep rolling for this small-cap biotech stock.

Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog

Is Exelixis, Inc. Stock a Bad News Buy?

Is the 75% drop in Exelixis, Inc. stock justified? Two of our top analysts weigh in and discuss the company's potential as a "bad news buy".

See More EXEL News...

EXEL's Top Competitors

EXEL $1.76 (0.00%)
Current stock: EXEL
TMO $128.66 (0.00%)
Current stock: TMO
$0.00 (0.00%)
Current stock:
ILMN $191.90 (0.00%)
Current stock: ILMN